Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Another day, another Brexit delay – so what happens now?

Health Secretary Matt Hancock maintains UK will retain regulatory collaboration with EMA

- PMLiVE

Merus makes case for bispecific antibody in specific cancer gene fusion

Could become a potential treatment for hard-to-treat cancers

Externalities

Improving my health through your own behaviour is not easy

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

- PMLiVE

NICE considering re-evaluation of quality of life assessment

Will address concerns around the watchdog's methodologies

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

- PMLiVE

UK government raises concerns about Illumina’s $1.2bn takeover of PacBio

CMA concludes the merger will result in loss of market competition

- PMLiVE

Assessing the risks in annuity pricing models

The challenge of adapting pricing models to accommodate new therapies

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

Results of European study expected in 2022

- PMLiVE

New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare

The latest movers in healthcare comms

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links